GlassScriptPhysician profile
Cyril Kuriakose
NPI 1255536181
$35,607.13
in general payments reported to CMS, 2019-2025
30 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $2,116 · 2021: $4,298 · 2022: $1,050 · 2023: $138 · 2024: $425 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $375 · Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $375.00 |
| Food and Beverage | $340.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $28,893.14 | 2019-2024 | Veltassa |
| Veloxis Pharmaceuticals, INC. | $4,704.98 | 2020-2022 | |
| Becton, Dickinson and Company | $375.00 | 2024 | |
| Amgen INC. | $178.75 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $130.42 | 2019 | |
| Mallinckrodt Hospital Products INC. | $128.72 | 2020-2023 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $115.07 | 2019-2025 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $112.85 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $112.02 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $111.46 | 2025 | |
| Opko Pharmaceuticals, LLC | $80.00 | 2020-2023 | Rayaldee |
| Akebia Therapeutics INC | $64.77 | 2021-2023 | Auryxia |
| Octapharma USA, INC. | $46.01 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $41.53 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $40.77 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.40 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $32.90 | 2019-2020 | |
| Nuwellis, INC. | $27.87 | 2022 | |
| Travere Therapeutics, INC. | $27.53 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.27 | 2020 | |
| Glaxosmithkline, LLC. | $22.93 | 2020 | |
| Cycle Pharmaceuticals INC | $21.27 | 2024 | Tiopronin |
| Baxter Healthcare | $21.25 | 2020 | |
| Xeris Pharmaceuticals, INC. | $20.89 | 2022 | |
| Eusa Pharma (US) LLC | $20.77 | 2022 | |
| Aurinia Pharma U.S., INC. | $18.39 | 2023 | Lupkynis |
| Arbor Pharmaceuticals, INC. | $17.53 | 2019 | |
| Ani Pharmaceuticals, INC. | $15.03 | 2022 | |
| Horizon Therapeutics Plc | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cyril Kuriakose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.